{"disease":{"id":"immune-checkpoint-inhibitors-icis","name":"immune checkpoint inhibitors icis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07141056","title":"The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Guilin Medical University, China","has_results":false},{"nct_id":"NCT06814548","title":"Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Yongxu Jia","has_results":false},{"nct_id":"NCT06675201","title":"Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":165,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT06951646","title":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}